Medication info

Pregabalin Capsule 75 mg

Prescription medicationHard capsuleExpired
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
KMS Pharmaceutical Co., Ltd.
Appearance
Hard capsule with the upper part brownish yellow and the lower part white, containing white powder
Packaging
Domestic - 30 capsules/bottle, Domestic - 60 capsules/bottle
Approval status
Expired

MFDS item code 201908673 · Approved 2019.12.27

This product's status changed to Expired on 2024.12.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures
Who uses it
Adults · Children
Adult dosage
This medication is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medication is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration schedule. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.
Children's dosage
Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
KMS Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial-onset seizures

  • Peripheral neuropathic pain
  • central neuropathic pain
  • epilepsy
  • secondary generalized symptoms
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults and is used as an adjunctive therapy for partial seizures with or without secondary generalized symptoms in epilepsy patients. It is also effective in treating fibromyalgia. This medication helps with various neurological disorders and pain management.

Dosage and Administration

Adult dosage

This medication is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this medication is excreted primarily by the kidneys, the dose should be adjusted in patients with impaired renal function. (Refer to “5. Patients with Renal Impairment”) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (Refer to “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies were also conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is excreted primarily by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula: Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine (mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration schedule Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150 mg/day, maximum dose 600 mg/day, BID or TID ≥30-<60: Starting dose 75 mg/day, maximum dose 300 mg/day, BID or TID ≥15-<30: Starting dose 25-50 mg/day, maximum dose 150 mg/day, QD or BID <15: Starting dose 25 mg/day, maximum dose 75 mg/day, QD Supplemental dose after hemodialysis: Starting dose 25 mg, maximum dose 100 mg, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the administration schedule. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Older Adults (65 years of age and older) Dose reduction may be necessary in older adults with impaired renal function.

Children's dosage

Children under 12 years of age: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.

Precautions

This medication may increase the risk of suicidal thoughts or behavior; therefore, if mood changes or unusual behavior occur during treatment, consult a doctor immediately. This medication should not be used if there is an allergy to any of the ingredients contained. Patients with certain genetic problems such as lactose intolerance should not take this medication. Diabetic patients may need to adjust the dosage of blood sugar control medications due to weight gain. If serious allergic reactions such as angioedema occur, discontinue the medication immediately and inform medical personnel. Elderly patients are at higher risk of injury due to dizziness or drowsiness from taking this medication. This medication may cause temporary blurred vision or changes in eyesight; if these symptoms occur, consult a doctor. Discontinuation of this medication should be gradual to avoid withdrawal symptoms such as insomnia, headache, and anxiety; do so under medical supervision. Patients with a history of drug abuse are at higher risk for misuse or dependence on this medication, and caution is required during use. Patients with impaired kidney function may require dosage adjustments. Patients with heart disease should use caution when taking this medication. Caution is advised when used in combination with opioid analgesics as it may increase central nervous system depressant effects. This medication poses a risk of respiratory depression; consult a doctor if there are respiratory disorders or kidney problems. During early pregnancy, there may be a risk of fetal malformation; therefore, women who are pregnant or planning to become pregnant should consult a physician and use effective contraception. During breastfeeding, this medication may be transmitted through breast milk, so consult medical personnel regarding the nursing status and medication use. It is advisable to avoid activities that require caution such as driving or operating machinery until dizziness or drowsiness has resolved after taking this medication. If severe rashes or swelling occur, discontinue the medication immediately and inform medical personnel. In case of overdose, symptoms such as drowsiness, confusion, and seizures may occur; seek emergency treatment immediately. This medication should be kept out of the reach of children, and it is safe not to transfer it to another container.

Side effects

  • Suicidal ideation
  • suicidal behavior
  • depression
  • abnormal changes in mood and behavior
  • angioedema
  • facial swelling
  • perioral edema
  • upper airway edema
  • dizziness
  • drowsiness
Show 217 more
  • loss of consciousness
  • confusion
  • mental disorder
  • blurred vision
  • changes in vision
  • insomnia
  • headache
  • nausea
  • anxiety
  • diarrhea
  • influenza-like syndrome
  • restlessness
  • depression
  • suicidal thoughts
  • pain
  • seizures
  • hyperhidrosis
  • misuse
  • abuse
  • dependence
  • congestive heart failure
  • severe respiratory depression
  • rhinitis
  • neutropenia
  • increased appetite
  • anorexia
  • hypoglycemia
  • confusion
  • disorientation
  • irritability
  • depression
  • moderate contentment
  • decreased libido
  • insomnia
  • depersonalization
  • hypersexuality
  • restlessness
  • agitation
  • mood swings
  • low affect
  • elevated affect
  • difficulty finding appropriate terms
  • hallucinations
  • abnormal dreams
  • increased libido
  • panic attack
  • inability to inhibit
  • apathy
  • dizziness
  • drowsiness
  • ataxia
  • abnormal motor coordination
  • balance disorder
  • amnesia
  • attention disorder
  • memory impairment
  • tremors
  • dysarthria
  • sensory disturbances
  • sensory loss
  • sedation
  • somnolence
  • cognitive impairment
  • nystagmus
  • speech disorder
  • myoclonic jerks
  • reduced reflexes
  • movement disorders
  • psychomotor agitation
  • positional vertigo
  • hypersensitivity
  • burning sensation
  • activity tremor
  • syncope
  • stupor
  • hypokinesia
  • olfactory disturbances
  • taste loss
  • writing difficulties
  • blurred vision
  • double vision
  • indirect vision loss
  • visual disturbances
  • visual field loss
  • photophobia
  • dry eyes
  • conjunctival swelling
  • vision reduction
  • eye pain
  • eye fatigue
  • increased tear secretion
  • eye irritation
  • mydriasis
  • during vibration
  • changes in depth perception
  • strabismus
  • brightness of vision
  • vertigo
  • auditory hypersensitivity
  • first-degree AV block
  • tachycardia
  • sinus bradycardia
  • sinus tachycardia
  • sinus arrhythmia
  • hypotension
  • hypertension
  • flushing
  • facial flushing
  • peripheral coldness
  • dyspnea
  • epistaxis
  • cough
  • nasal congestion
  • rhinitis
  • snoring
  • pharyngeal tension
  • nasal dryness
  • respiratory depression
  • vomiting
  • abdominal distension
  • constipation
  • dry mouth
  • bloating
  • excessive salivation
  • gastroesophageal reflux disease
  • oral sensory loss
  • ascites
  • dysphagia
  • pancreatitis
  • sweating
  • papular rash
  • urticaria
  • cold sweats
  • muscle cramps
  • arthralgia
  • back pain
  • limb pain
  • cervical spasms
  • joint swelling
  • myalgia
  • muscle spasm
  • neck pain
  • muscle rigidity
  • rhabdomyolysis
  • urinary disorders
  • urinary incontinence
  • decreased urination
  • renal failure
  • erectile dysfunction
  • delayed ejaculation
  • sexual dysfunction
  • dysmenorrhea
  • amenorrhea
  • mastalgia
  • nipple discharge
  • gynecomastia
  • peripheral edema
  • edema
  • gait abnormalities
  • falls
  • feeling of intoxication
  • altered sensations
  • fatigue
  • chest tightness
  • generalized edema
  • pain
  • fever
  • chills
  • weakness
  • thirst
  • weight gain
  • increased alanine aminotransferase
  • increased creatine phosphokinase
  • increased aspartate aminotransferase
  • increased blood sugar
  • decreased platelet count
  • decreased potassium in the blood
  • weight loss
  • increased blood creatinine
  • decreased white blood cell count
  • hypersensitivity
  • allergic reactions
  • headache
  • keratitis
  • pulmonary edema
  • tongue swelling
  • itching
  • Stevens-Johnson syndrome
  • toxic epidermal necrolysis
  • urinary retention
  • gynecomastia
  • malaise
  • delirium
  • paralysis
  • affective disorder
  • drowsiness
  • confused state
  • agitation
  • restlessness
  • worsening of convulsions
  • gastrointestinal disorders
  • tinnitus
  • sleep disorders
  • skin disorders
  • increased BUN
  • blood in stool
  • fatigue
  • weakness
  • gait abnormalities
  • decreased libido
  • sleep disorders
  • insomnia
  • ataxia
  • speech impairments
  • sensory disturbances
  • memory impairment
  • attention disorder

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best to maintain a storage temperature between 15 degrees and 30 degrees Celsius (room temperature).

Appearance and packaging

Appearance

Hard capsule with the upper part brownish yellow and the lower part white, containing white powder

Package unit

Domestic - 30 capsules/bottle, Domestic - 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.